Avedro celebrates their 1 year anniversary of the commercial availability of Photrexa Viscous and Photrexa, drugs used in corneal cross-linking with the KXL System, for the treatment of progressive keratoconus. It’s estimated that 10,000 procedures have been completed.

WALTHAM, Mass.–(BUSINESS WIRE)–Avedro, Inc., today marked the one year anniversary of the U.S. commercial availability of Photrexa Viscous® (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution), the drugs used in corneal cross-linking with the KXL® System, for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. In that period, Avedro estimates that 10,000 procedures have been completed at more than 250 sites. Click below to read more!